Wyeth Manufacturing Capacity Serves As Lure For Biotech Deals, Essner Says
Executive Summary
Wyeth's manufacturing capacity makes it an attractive partner for biotech products, Wyeth CEO Robert Essner said at Morgan Stanley's Pharmaceutical CEOs Unplugged conference in New York City
You may also be interested in...
Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys
Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3
Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys
Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated